Dr Reddy’s Q1FY27 profit falls 69% as US sales and semaglutide supply weaken
Dr Reddy’s reported Q1FY27 net profit of ₹443 crore, down 69% year-on-year, with revenue falling 5.6% to ₹8,071 crore. US revenue dropped 35%, while India, Europe and emerging markets posted double-digit growth. The company expects semaglutide supply to potentially resume around November.
Dr Reddy’s Q1FY27 profit fell 69% as US sales and generic semaglutide supply were hit. India, Europe and emerging markets grew in double digits. The company expects to resume semaglutide supply around November and is pursuing inorganic growth opportunities.
Why this matters
No related recent signals were provided. Q1FY27 results highlight Dr Reddy’s exposure to US sales and semaglutide supply despite double-digit growth in India, Europe and emerging markets.
Retail-company signals are accelerating, up 1,012,500% QoQ.